S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
66,000% upside on tiny biotech? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
66,000% upside on tiny biotech? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
California Gov. Gavin Newsom rejects bill that would have given unemployment checks to some striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
66,000% upside on tiny biotech? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
66,000% upside on tiny biotech? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
California Gov. Gavin Newsom rejects bill that would have given unemployment checks to some striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
66,000% upside on tiny biotech? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
66,000% upside on tiny biotech? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
California Gov. Gavin Newsom rejects bill that would have given unemployment checks to some striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
66,000% upside on tiny biotech? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
66,000% upside on tiny biotech? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
California Gov. Gavin Newsom rejects bill that would have given unemployment checks to some striking workers
NASDAQ:IONS

Ionis Pharmaceuticals (IONS) Stock Forecast, Price & News

$45.36
-0.90 (-1.95%)
(As of 09/29/2023 ET)
Compare
Today's Range
$45.22
▼
$47.00
50-Day Range
$38.50
▼
$47.13
52-Week Range
$32.69
▼
$47.74
Volume
1.34 million shs
Average Volume
1.05 million shs
Market Capitalization
$6.49 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.45
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Ionis Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
9.0% Upside
$49.45 Price Target
Short Interest
Bearish
6.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.58
Upright™ Environmental Score
News Sentiment
0.61mentions of Ionis Pharmaceuticals in the last 14 days
Based on 36 Articles This Week
Insider Trading
Selling Shares
$1.62 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.35) to ($3.56) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.19 out of 5 stars

Medical Sector

950th out of 972 stocks

Pharmaceutical Preparations Industry

444th out of 453 stocks

See Top Rated MarketRank™ Stocks Here

IONS stock logo

About Ionis Pharmaceuticals (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.

IONS Price History

IONS Stock News Headlines

October 1, 2023 | americanbankingnews.com
C Frank Bennett Sells 4,460 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock
October 1, 2023 | americanbankingnews.com
B Lynne Parshall Sells 10,000 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock
October 1, 2023 | Porter and Company (Ad)
The Elites Are Waging War on Elon Musk — Here's Why…
Elon has helped unleash an opportunity that could create trillions in wealth for everyday Americans. So why does the deep state hate him for it?
September 30, 2023 | msn.com
Raymond James Initiates Coverage of Ionis Pharmaceuticals (IONS) with Strong Buy Recommendation
September 30, 2023 | finance.yahoo.com
Insider Sell: EVP, Chief Scientific Officer C Bennett Sells 4,460 Shares of Ionis ...
September 30, 2023 | americanbankingnews.com
Ionis Pharmaceuticals (NASDAQ:IONS) Stock Rating Reaffirmed by Needham & Company LLC
September 30, 2023 | americanbankingnews.com
Leerink Partnrs Analysts Lift Earnings Estimates for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
September 30, 2023 | americanbankingnews.com
Ionis Pharmaceuticals (NASDAQ:IONS) Coverage Initiated at Raymond James
October 1, 2023 | Chaikin Analytics (Ad)
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
September 29, 2023 | finance.yahoo.com
Insider Sell: Director B Parshall Sells 10,000 Shares of Ionis Pharmaceuticals Inc
September 28, 2023 | finance.yahoo.com
Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs
September 28, 2023 | finance.yahoo.com
Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit
September 28, 2023 | americanbankingnews.com
Morgan Stanley Increases Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $45.00
September 27, 2023 | msn.com
Ionis' metabolic disorder drug lowers high levels of a type of fat in study
September 27, 2023 | finance.yahoo.com
Strength Seen in Ionis Pharmaceuticals (IONS): Can Its 8.5% Jump Turn into More Strength?
September 27, 2023 | finance.yahoo.com
Ionis (IONS) Meets Rare Disease Drug Study Goal, Stock Up 8.5%
September 27, 2023 | finance.yahoo.com
Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease
September 26, 2023 | msn.com
Ionis Pharmaceuticals' Rare Metabolic Disorder Candidate Poised To Become New Standard Treatment, Study Shows Encouraging Action
September 26, 2023 | msn.com
Ionis late-stage rare disease data fails to impress Bernstein
September 26, 2023 | finance.yahoo.com
Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder
September 26, 2023 | reuters.com
Ionis Pharma's genetic disorder drug succeeds in late-stage study
September 26, 2023 | markets.businessinsider.com
Ionis Reports Positive Results From Phase 3 Study Of Olezarsen In Familial Chylomicronemia Syndrome
September 26, 2023 | reuters.com
Ionis Pharma's genetic disorder drug meets main goal in late-stage study
September 26, 2023 | finance.yahoo.com
Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome
September 26, 2023 | finance.yahoo.com
UPDATE 2-Ionis' metabolic disorder drug lowers high levels of a type of fat in study
September 21, 2023 | americanbankingnews.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Recommendation of "Hold" by Analysts
September 21, 2023 | americanbankingnews.com
Leerink Partnrs Comments on Ionis Pharmaceuticals, Inc.'s Q3 2023 Earnings (NASDAQ:IONS)
See More Headlines
Receive IONS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IONS Company Calendar

Last Earnings
8/09/2023
Today
10/01/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IONS
CUSIP
46433010
CIK
874015
Web
www.ionispharma.com
Phone
(760) 931-9200
Fax
760-603-2700
Employees
796
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$49.45
High Stock Price Forecast
$67.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+9.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
10 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.17)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-269,720,000.00
Net Margins
-48.81%
Pretax Margin
-44.60%
Return on Equity
-59.17%
Return on Assets
-11.40%

Debt

Debt-to-Equity Ratio
3.07
Current Ratio
9.09
Quick Ratio
9.00

Sales & Book Value

Annual Sales
$587 million
Price / Sales
11.06
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.03 per share
Price / Book
11.26

Miscellaneous

Outstanding Shares
143,100,000
Free Float
139,308,000
Market Cap
$6.49 billion
Optionable
Optionable
Beta
0.51
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Brett P. Monia Ph.D. (Age 62)
    Founder, CEO & Director
    Comp: $1.71M
  • Ms. Elizabeth L. Hougen M.A.Ms. Elizabeth L. Hougen M.A. (Age 61)
    M.B.A., M.S., Exec. VP of Fin. & CFO
    Comp: $1.02M
  • Ms. Onaiza Cadoret-Manier M.A. (Age 58)
    M.B.A., M.S., Exec. VP, Chief Global Product Strategy & Operations Officer
    Comp: $930.82k
  • Ms. B. Lynne Parshall Esq.Ms. B. Lynne Parshall Esq. (Age 69)
    J.D., Sr. Strategic Advisor & Director
    Comp: $334.64k
  • Dr. Richard S. Geary Ph.D. (Age 65)
    Exec. VP & Chief Devel. Officer
    Comp: $946.26k
  • Mr. Joseph T. Baroldi M.A. (Age 44)
    M.B.A., M.S., Exec. VP & Chief Bus. Officer
    Comp: $815.87k
  • Mr. Darren Gonzales
    Chief Accounting Officer & Sr. VP
  • Dr. C. Frank Bennett BSc (Age 66)
    Ph.D., Exec. VP & Chief Scientific Officer
  • Mr. D. Wade Walke Ph.D.
    Sr. VP of Investor Relations
  • Mr. Patrick R. O'Neil Esq. (Age 49)
    Exec. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













IONS Stock - Frequently Asked Questions

Should I buy or sell Ionis Pharmaceuticals stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IONS shares.
View IONS analyst ratings or view top-rated stocks.

What is Ionis Pharmaceuticals' stock price forecast for 2023?

10 Wall Street analysts have issued 12 month target prices for Ionis Pharmaceuticals' stock. Their IONS share price forecasts range from $27.00 to $67.00. On average, they expect the company's share price to reach $49.45 in the next year. This suggests a possible upside of 9.0% from the stock's current price.
View analysts price targets for IONS or view top-rated stocks among Wall Street analysts.

How have IONS shares performed in 2023?

Ionis Pharmaceuticals' stock was trading at $37.77 at the beginning of the year. Since then, IONS stock has increased by 20.1% and is now trading at $45.36.
View the best growth stocks for 2023 here.

When is Ionis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our IONS earnings forecast.

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its quarterly earnings data on Wednesday, August, 9th. The company reported $0.60 EPS for the quarter, beating the consensus estimate of ($0.94) by $1.54. The firm had revenue of $188 million for the quarter, compared to analysts' expectations of $136.84 million. Ionis Pharmaceuticals had a negative trailing twelve-month return on equity of 59.17% and a negative net margin of 48.81%.

What ETFs hold Ionis Pharmaceuticals' stock?

ETFs with the largest weight of Ionis Pharmaceuticals (NASDAQ:IONS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Morningstar US Small Growth (MSGR), First Trust NYSE Arca Biotechnology Index Fund (FBT), Horizon Kinetics Medical ETF (MEDX), Franklin Genomic Advancements ETF (HELX), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC) and VanEck Morningstar SMID Moat ETF (SMOT).

What guidance has Ionis Pharmaceuticals issued on next quarter's earnings?

Ionis Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $575.00M-, compared to the consensus revenue estimate of $586.28 million.

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $45.36.

How much money does Ionis Pharmaceuticals make?

Ionis Pharmaceuticals (NASDAQ:IONS) has a market capitalization of $6.49 billion and generates $587 million in revenue each year. The company earns $-269,720,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis.

How many employees does Ionis Pharmaceuticals have?

The company employs 796 workers across the globe.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The official website for the company is www.ionispharma.com. The company can be reached via phone at (760) 931-9200, via email at wwalke@ionisph.com, or via fax at 760-603-2700.

This page (NASDAQ:IONS) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -